Incyte 4Q Net Up on Higher Revenue

Dow Jones02-10 20:22

By Rob Curran

Incyte's fourth-quarter earnings rose on higher demand for its Jakafi cancer drug and other products.

The maker of cancer drugs and other pharmaceuticals posted net income of $299.3 million, or $1.46 a share, up from $201.2 million, or $1.02 a share, a year earlier.

Excluding certain one-off items, the company logged adjusted earnings of $1.80 a share, shy of the mean analyst estimate of $1.90 a share, as per FactSet.

Revenue rose 28% to $1.51 billion, topping the average analyst target of $1.36 billion, according to FactSet. Revenue for its Jakafi product, used to treat certain kinds of blood and bone-marrow cancer, rose 7% to $828.2 million. Sales of Opzelura prescription skin cream rose 28% to $207.3 million.

For 2026, Incyte projected net product revenue in a range between $4.77 billion and $4.94 billion. That includes Jakafi revenue in a range between $3.22 billion and $3.27 billion.

In the first quarter, Incyte expects to submit a commercialization application for its povorcitinib product for the treatment of a skin condition to the Food and Drug Administration for review.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

February 10, 2026 07:22 ET (12:22 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610647919?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610647919","market":"nz","top_or_hot":-1,"title":"Incyte 4Q Net Up on Higher Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Incyte's fourth-quarter earnings rose on higher demand for its Jakafi cancer drug and other products. \n</p>\n<p>\n  The maker of cancer drugs and other pharmaceuticals posted net income of $299.3 million, or $1.46 a share, up from $201.2 million, or $1.02 a share, a year earlier. \n</p>\n<p>\n  Excluding certain one-off items, the company logged adjusted earnings of $1.80 a share, shy of the mean analyst estimate of $1.90 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 28% to $1.51 billion, topping the average analyst target of $1.36 billion, according to FactSet. Revenue for its Jakafi product, used to treat certain kinds of blood and bone-marrow cancer, rose 7% to $828.2 million. Sales of Opzelura prescription skin cream rose 28% to $207.3 million. \n</p>\n<p>\n  For 2026, Incyte projected net product revenue in a range between $4.77 billion and $4.94 billion. That includes Jakafi revenue in a range between $3.22 billion and $3.27 billion. \n</p>\n<p>\n  In the first quarter, Incyte expects to submit a commercialization application for its povorcitinib product for the treatment of a skin condition to the Food and Drug Administration for review. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2026 07:22 ET (12:22 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte 4Q Net Up on Higher Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte 4Q Net Up on Higher Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-10 20:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Incyte's fourth-quarter earnings rose on higher demand for its Jakafi cancer drug and other products. \n</p>\n<p>\n  The maker of cancer drugs and other pharmaceuticals posted net income of $299.3 million, or $1.46 a share, up from $201.2 million, or $1.02 a share, a year earlier. \n</p>\n<p>\n  Excluding certain one-off items, the company logged adjusted earnings of $1.80 a share, shy of the mean analyst estimate of $1.90 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 28% to $1.51 billion, topping the average analyst target of $1.36 billion, according to FactSet. Revenue for its Jakafi product, used to treat certain kinds of blood and bone-marrow cancer, rose 7% to $828.2 million. Sales of Opzelura prescription skin cream rose 28% to $207.3 million. \n</p>\n<p>\n  For 2026, Incyte projected net product revenue in a range between $4.77 billion and $4.94 billion. That includes Jakafi revenue in a range between $3.22 billion and $3.27 billion. \n</p>\n<p>\n  In the first quarter, Incyte expects to submit a commercialization application for its povorcitinib product for the treatment of a skin condition to the Food and Drug Administration for review. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2026 07:22 ET (12:22 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610647919","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610647919","pubTimestamp":1770726120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Incyte's fourth-quarter earnings rose on higher demand for its Jakafi cancer drug and other products.The maker of cancer drugs and other pharmaceuticals posted net income of $299.3 million, or $1.46 a share, up from $201.2 million, or $1.02 a share, a year earlier.Excluding certain one-off items, the company logged adjusted earnings of $1.80 a share, shy of the mean analyst estimate of $1.90 a share, as per FactSet.Revenue rose 28% to $1.51 billion, topping the average analyst target of $1.36 billion, according to FactSet. Revenue for its Jakafi product, used to treat certain kinds of blood and bone-marrow cancer, rose 7% to $828.2 million. Sales of Opzelura prescription skin cream rose 28% to $207.3 million.For 2026, Incyte projected net product revenue in a range between $4.77 billion and $4.94 billion. That includes Jakafi revenue in a range between $3.22 billion and $3.27 billion.In the first quarter, Incyte expects to submit a commercialization application for its povorcitinib pro","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗"},"translate_title":"Incyte第四季度净收入增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1.5},"content_text":"By Rob Curran \n\n\n \n\n\n  Incyte's fourth-quarter earnings rose on higher demand for its Jakafi cancer drug and other products. \n\n\n  The maker of cancer drugs and other pharmaceuticals posted net income of $299.3 million, or $1.46 a share, up from $201.2 million, or $1.02 a share, a year earlier. \n\n\n  Excluding certain one-off items, the company logged adjusted earnings of $1.80 a share, shy of the mean analyst estimate of $1.90 a share, as per FactSet. \n\n\n  Revenue rose 28% to $1.51 billion, topping the average analyst target of $1.36 billion, according to FactSet. Revenue for its Jakafi product, used to treat certain kinds of blood and bone-marrow cancer, rose 7% to $828.2 million. Sales of Opzelura prescription skin cream rose 28% to $207.3 million. \n\n\n  For 2026, Incyte projected net product revenue in a range between $4.77 billion and $4.94 billion. That includes Jakafi revenue in a range between $3.22 billion and $3.27 billion. \n\n\n  In the first quarter, Incyte expects to submit a commercialization application for its povorcitinib product for the treatment of a skin condition to the Food and Drug Administration for review. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 07:22 ET (12:22 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610647919","isCrawlerRequest":true}